Events After the End of the Reporting Period


On April 6, 2017, Bayer decided to terminate its option right relating to the late-stage development and commercialization of biopharmaceutical Wnt pathway inhibitors under its collaboration with OncoMed Pharmaceuticals Inc., United States. In this connection, impairment losses of €69 million were recognized at the start of the second quarter of 2017.

Repayment of financial liabilities

On April 5, 2017, Bayer Holding Ltd., Japan, repaid on schedule a bond with a nominal volume of JPY 30 billion.

Leverkusen, April 25, 2017
Bayer Aktiengesellschaft

The Board of Management

Werner Baumann

Liam Condon

Johannes Dietsch

Dr. Hartmut Klusik

Kemal Malik

Erica Mann

Dieter Weinand